MY170829A - Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria - Google Patents

Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria

Info

Publication number
MY170829A
MY170829A MYPI2014702359A MYPI2014702359A MY170829A MY 170829 A MY170829 A MY 170829A MY PI2014702359 A MYPI2014702359 A MY PI2014702359A MY PI2014702359 A MYPI2014702359 A MY PI2014702359A MY 170829 A MY170829 A MY 170829A
Authority
MY
Malaysia
Prior art keywords
resistant bacteria
drug resistant
inhibition
treatment
fulvic acid
Prior art date
Application number
MYPI2014702359A
Other languages
English (en)
Inventor
Stephen William Leivers
Peter Warn
Original Assignee
Pfeinsmith Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeinsmith Ltd filed Critical Pfeinsmith Ltd
Publication of MY170829A publication Critical patent/MY170829A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014702359A 2012-03-07 2013-03-06 Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria MY170829A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA201201683 2012-03-07

Publications (1)

Publication Number Publication Date
MY170829A true MY170829A (en) 2019-09-05

Family

ID=48142838

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014702359A MY170829A (en) 2012-03-07 2013-03-06 Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria

Country Status (8)

Country Link
US (1) US9265744B2 (enExample)
EP (1) EP2822551B1 (enExample)
KR (1) KR20140135813A (enExample)
CN (1) CN104203227A (enExample)
IN (1) IN2014DN07194A (enExample)
MY (1) MY170829A (enExample)
RU (1) RU2640928C2 (enExample)
WO (1) WO2013132444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
CN109706195B (zh) * 2018-12-27 2022-04-08 齐齐哈尔龙江阜丰生物科技有限公司 颗粒型苏氨酸的生产工艺
CN111616358A (zh) * 2020-06-20 2020-09-04 田劭军 一种用于提高免疫力的组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225271A (en) 1987-07-08 1991-02-26 Nat Energy Council Oxidising coal using a gaseous oxidant
DE3903773A1 (de) 1988-02-11 1989-09-14 Nat Energy Council Eine mischung mit bakteriozider oder bakteriostatischer aktivitaet
US5204368A (en) 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
WO2000019999A1 (en) 1998-10-08 2000-04-13 Enerkom (Proprietary) Limited Fulvic acid and its use in the treatment of various conditions
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
WO2007125492A2 (en) * 2006-05-02 2007-11-08 Pfeinsmith S.A. (Pty) Ltd Acidic composition
US8445452B2 (en) * 2008-06-05 2013-05-21 Pfeinsmith Ltd. Fulvic acid and antibiotic combination

Also Published As

Publication number Publication date
RU2014140227A (ru) 2016-04-27
EP2822551A1 (en) 2015-01-14
KR20140135813A (ko) 2014-11-26
IN2014DN07194A (enExample) 2015-04-24
RU2640928C2 (ru) 2018-01-12
WO2013132444A1 (en) 2013-09-12
CN104203227A (zh) 2014-12-10
US20150031767A1 (en) 2015-01-29
EP2822551B1 (en) 2016-12-21
US9265744B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
WO2015114666A3 (en) Treatments for resistant acne
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
HK1209801A1 (en) Method for preventing and/or treating infections, colonisations, or illnesses related to staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans and/or malassezia furfur
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
BR112015013123A2 (pt) inibidores de beta-lactamase
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
BR112014027842A2 (pt) bacteriófago lisina e combinações de antibióticos contra bactérias gram-positivas
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX2019012877A (es) Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago.
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
BR112015027536A8 (pt) composição compreendendo bactérias ácidas lácticas para utilização no tratamento preventivo e/ou curativo de cistite recorrente.
WO2015024010A3 (en) Substituted hydroxamic acid compounds
HK1201836A1 (en) Novel pyrrole derivatives
MY170829A (en) Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
WO2015024011A3 (en) Antibacterial compounds
AU2012335397A8 (en) Novel bacteriophages
MY180113A (en) Use of patchouli extract in the preparation of compositions with an anti-microorganism effect
BR112015030072A2 (pt) uma composiçaõ farmacêutica para a profilaxia e o tratamento de doenças de etiologia infecciosa
AU2018362978A1 (en) Beta-hairpin peptidomimetics
MX2016005869A (es) Inhibidor de beta-lactamasa cristalina.
RU2015133469A (ru) Антимикробная комбинация в отношении устойчивых к карбапенемам грамотрицательных микроорганизмов, продуцирующих металло-β-лактамазу
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
HK1229697A1 (en) Synergistic bacterial compositions and methods of production and use thereof